** Shares of cancer test maker Exact Sciences fall 27.3% to $52 after the bell
** Cuts 2024 total revenue forecast; to be in the range of $2.73 bln to $2.75 bln vs prior estimate of $2.81 bln to $2.85 bln
** Company reports Q3 revenue of $709 mln, missing estimates of $717.7 mln, according to data compiled by LSEG
** Cuts revenue guidance for its screening segment to $2.08 bln to $2.1 bln from its prior guidance of $2.16 bln to $2.18 bln
** "Our execution during the third quarter and updated outlook for the full year don’t reflect our full potential. We plan to accelerate growth in 2025, and our long-term outlook remains strong" - EXAS
** Up to last close, share are down 3.3% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。